Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting
04 avr. 2017 08h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, April 04, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today...
Poseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory Affairs
03 janv. 2017 09h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced...
Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting
05 déc. 2016 13h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today...
Poseida Therapeutics to Present Three Abstracts on Novel BCMA-Specific CAR-T Therapy at American Society of Hematology 2016 Annual Meeting
03 nov. 2016 09h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today...
Poseida Therapeutics Establishes Scientific Advisory Board
08 sept. 2016 07h30 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics,...
Poseida Therapeutics Expands Executive Leadership Team
18 août 2016 07h30 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Aug. 18, 2016 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics,...
Poseida Therapeutics Announces Series A Financing
16 déc. 2015 09h00 HE
|
Poseida Therapeutics, Inc.
LA JOLLA, Calif., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (“Poseida”), a US-based, privately-held, human therapeutics company focused on the development of novel therapies using...
Poseida Therapeutics, Inc. Announces Worldwide License Agreement With Janssen to Apply Centyrin Technology in the Development of Chimeric Antigen Receptor (CAR) Therapies
11 août 2015 06h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (Poseida), a private biotechnology company spun out of Transposagen Biopharmaceuticals, Inc. (Transposagen), and headquartered...
Poseida Therapeutics, Inc., Expands Board of Directors
05 août 2015 16h27 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (Poseida), a privately-held human therapeutics spinout of Transposagen Biopharmaceuticals, Inc. (Transposagen), announces the...
Poseida Therapeutics to Participate in Jefferies 2015 Healthcare Conference
01 juin 2015 11h15 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, June 1, 2015 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. ("Poseida"), a privately-held human therapeutics spinout of Transposagen Biopharmaceuticals, Inc. ("Transposagen"), announces...